Citigroup Inc Terns Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 49,655 shares of TERN stock, worth $282,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,655

Previous 361,080 86.25%

Holding current value

$282,040

Previous $2.46 Million 83.16%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$6.49 - $10.8 $2.02 Million - $3.36 Million	-311,425 Reduced 86.25%	49,655 $414,000
Q2 2024 Aug 12, 2024	BUY	$4.54 - $8.2 $923,976 - $1.67 Million	203,519 Added 129.17%	361,080 $2.46 Million
Q1 2024 May 10, 2024	BUY	$4.86 - $8.19 $731,269 - $1.23 Million	150,467 Added 2121.05%	157,561 $1.03 Million
Q4 2023 Feb 09, 2024	BUY	$3.37 - $6.86 $21,086 - $42,923	6,257 Added 747.55%	7,094 $46,000
Q3 2023 Nov 09, 2023	SELL	$4.7 - $8.55 $64,258 - $116,895	-13,672 Reduced 94.23%	837 $4,000
Q2 2023 Aug 10, 2023	SELL	$7.35 - $13.29 $226,997 - $410,448	-30,884 Reduced 68.04%	14,509 $126,000
Q1 2023 May 11, 2023	SELL	$7.91 - $12.0 $5,181 - $7,860	-655 Reduced 1.42%	45,393 $537,000
Q4 2022 Feb 09, 2023	BUY	$4.62 - $10.18 $209,503 - $461,632	45,347 Added 6468.9%	46,048 $468,000
Q3 2022 Nov 10, 2022	BUY	$1.87 - $6.42 $340 - $1,168	182 Added 35.07%	701 $4,000
Q2 2022 Aug 10, 2022	SELL	$1.5 - $3.0 $822 - $1,644	-548 Reduced 51.36%	519 $1,000
Q1 2022 May 12, 2022	SELL	$2.83 - $6.7 $9,109 - $21,567	-3,219 Reduced 75.1%	1,067 $3,000
Q4 2021 Feb 10, 2022	BUY	$5.65 - $10.73 $15,221 - $28,906	2,694 Added 169.22%	4,286 $30,000
Q3 2021 Nov 10, 2021	BUY	$7.22 - $13.46 $11,494 - $21,428	1,592 New	1,592 $17,000

Others Institutions Holding TERN

# of Institutions

167

Shares Held

78.3M

Call Options Held

580K

Put Options Held

454K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $214M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account